EU Commission Approval for New Strengths Of Avandametà for Type 2 Diabetes
Supportive Care for Cancer Treatments In appendage to anti-tumor agents, chemotherapy involve supportive nurture to alleviate side effects. For illustration, erythropoietin is in the previous relevant to counterbalance a droplet in red blood cells, G-CSF to instigate white blood cell obtain, and serotonin antagonists to bar the nausea and vomiting caused by chemotherapy.
“GlaxoSmithKline be with cloud nine with the European Commission’s approbation today of the new AVANDAMET 1 gram tablets for the treatment of type 2 diabetes. These new dosages will tender greater dose adaptableness by providing a more all-encompassing span of tablet strengths to the copious type 2 diabetes patients who be at the moment taking AVANDAMET or AVANDIA plus metformin. The new AVANDAMET 1g formulation may also offer greater accommodating ease of access by reducing the numeral of pills to be taken, potentially following in enhanced patient toll,” said Andrew Witty, President of GlaxoSmithKline Pharmaceuticals Europe.
Prague, Czech Republic, Monday, 27th September 2004, 08.00 CET - The person over you efficacy of esomeprazole (Nexiumî) done pantoprazole be unequivocally demonstrated today when the packed grades of a head-to-head office be revealed contained by choose of the opening circumstance.
“These new dosage strengths of rosiglitazone and metformin in one pill will aid clinicians up to date their type 2 diabetes patients a more convenient method of attempt a break above glycaemic normalize.” AVANDAMET is the most primitive treatment that combines a thiazolidinedione - AVANDIA (rosiglitazone maleate) - with a primary oral diabetes psychiatric help - metformin - in one convenient pill. AVANDIA target insulin antagonism,1-4 an underlying rationale of type 2 diabetes, whereas metformin works largely by reducing the amount of blood sugar produced by the liver.5 Together, the two drugs help patients achieve enhanced glucose control compare to metformin alone.6 Good glucose control may help to rein in the undertaking of more than a few long-term complications associated with type 2 diabetes.7 In combination, the blend of AVANDIA plus metformin has be shown to have a minimal risk of hypoglycaemia (low blood sugar),8 a loin effect generally see with sulphonylureas.9 AVANDAMET be originally approved in the European Union in October 2003 for the treatment of type 2 diabetes mellitus, surprisingly in portly patients, who are uncontrolled on their maximally tolerate dose of metformin alone. AVANDAMET is currently available in two tablet strengths of rosiglitazone/metformin: 1 mg/500 mg, 2 mg/500 mg.
